Apomorphine

Apomorphine is an aporphine alkaloid. Among its listed roles, it functions as a alpha-adrenergic drug, a serotonergic drug, an antidyskinesia agent, a dopamine agonist, an antiparkinson drug and an emetic. It is derived from a hydride of an aporphine. Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson’s. It was first synthesized in 1845 and first used in Parkinson’s disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders. Apomorphine was granted FDA approval on 20 April 2004. It is grouped under the following drug class(es): Dopamine agents. Its therapeutic use is listed as antiparkinsonian agents and central nervous system (CNS) agents. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Ixense, Apomorphinum and R-(-)-Apomorphine. Its PubChem CID is 6005.